LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug ...
LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug ...
Key opinion leader (KOL) input is associated with a higher success rate in drug development. However, many oncology programs fail to effectively use this critical resource, resulting in poor decision ...
IND approval allows for US trial sites and recruitment of eligible US patients to be added to EP0042’s ongoing phase 1/2 trial LONDON--(BUSINESS WIRE)--Ellipses Pharma (“Ellipses”), a global drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results